Pre-eclampsia

PlGF is promising in pre-eclampsia early detection.

Pre-eclampsia is a disorder of placental origin expressed during pregnancy and the postpartum period. It usually develops after the 20th week of pregnancy and the condition tends to progress rapidly. Pre-eclampsia is estimated to affect 8,370,000 women worldwide every year. As well as being a major cause of fetal and neonatal morbidity and mortality, pre-eclampsia is also a major threat to maternal health.

Due to the serious consequences of pre-eclampsia, multiple efforts are being made to combat the disorder by identifying effective markers for risk assessment, and selecting suitable medications to reduce the anticipated risks. Cases categorized as early onset PE are associated with the risk of severe complications, and though they represent only 30% of the total PE cases, they currently absorb 80% of the total PE health care costs. The focus is thus on finding early markers. Early detection means increased likelihood for better outcomes, in terms of severity, complete recovery, or severity reduction.

Placental growth factor (PlGF), shows potential for early detection of early onset PE.

For information about pre-eclampsia and the importance of early detection, please visit our dedicated pages: www.perkinelmer.com/pre-eclampsia

Products below may not be available in all countries. For information on availability, please contact your local representative.


View Technologies

PlGF Controls - outside USA only

Excellence in the QC materials used is critical to ensuring the integrity of results. For laboratories...  View more

PlGF Kits - outside USA only

Placental Growth Factor (PlGF) has been shown to be reduced in a high proportion of pregnancies destined...  View more